| April 2 |
FDA Approves Janumet for Type 2 Diabetes, Offering Powerful Glucose
Control of a DPP-4 Inhibitor and Metformin in a Single Tablet |
| April 2 |
Baxter Announces FDA Approval Of Ceprotin For Severe Congential
Protein C Deficiency |
| April 2 |
Interpublic to Participate in J&J Media Review |
| April 2 |
Novartis Suspends Canadian Marketing and Sales of Zelnorm in
Response to Request From Health Canada |
| April 2 |
Roche Acquires THP in $56.5 Million Deal |
| April 2 |
INEX Extends Timeline for Completing Spin-out of Tekmira
Pharmaceuticals Corporation |
| April 2 |
Abbott Seeks U.S. and E.U. Regulatory Approval for Humira
(Adalimumab) in Psoriasis |
| April 2 |
IMPAX Settles Oxycontin Litigation; Amends Marketing Agreement with
DAVA Pharmaceuticals |
| April 2 |
NeoPharm Provides Update on LE-SN38 Program |
| April 2 |
Cephalon Provides Update Related to Nuvigil New Drug Application |
| April 2 |
Auriga Laboratories Expects Q1 2007 Gross Revenue to Exceed a
Record $8 Million |
| April 2 |
EPIX Provides Update Regarding Status of Vasovist Appeal |
| April 2 |
Boehringer Ingelheim: Media Statement |
| April 2 |
The Transfer of All Commercial Rights for Panaldine |
| April 2 |
FDA Approves Rhophylac for the Treatment of Immune Thrombocytopenic
Purpura (ITP) |
| April 2 |
GlaxoSmithKline K.K. Seeks Approval in Japan for Lapatinib, a New
Treatment for Breast Cancer |
| April 2 |
FDA Approves Accelerated Dosing Schedule for GlaxoSmithKline's
Twinrix |
| April 2 |
Large Study Shows that Presence of Neutralizing Antibodies Did Not
Predict Clinical Response to Betaseron Treatment |
| April 2 |
Genencor's Technology for Production of Secreted Polypeptides
Licensed by Pfizer |
| April 2 |
Pharmaceutical Federal Lobbying Spending Flourishes |
| April 2 |
PerkinElmer Acquires Improvision Ltd. |
| April 2 |
Sun Pharma Announces Approval of Demerger by High Court and Fixing
of Record Date 30 April 2007 |
| April 2 |
Fitzpatrick Cella Wins Appeal on Behalf of Merck & Co. in
Trusopt Patent-Infringement Case |
| April 2 |
Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ;
Resolve Allegations of Improper Activities Prior to Acquisition by
Pfizer |
| April 2 |
Publicis Groupe to Expand Further in China: Acquires Majority Stake
in Yong Yang, Leading Marketing Services Group |
| April 2 |
Fitzpatrick Cella Wins Appeal on Behalf of Merck & Co. in
Trusopt Patent-Infringement Case |
| April 3 |
Once Daily, Extended-Release Ropinirole Improves Parkinson's
Symptoms in Patients not Optimally Controlled With Levodopa |
| April 3 |
Beijing Med-Pharm Corporation and Alliance Boots plc Joint Venture
Acquisition Plans Approved by Guangzhou Pharmaceuticals Company
Ltd. Shareholders |
| April 3 |
AmerisourceBergen to Acquire Xcenda LLC |
| April 3 |
Codexis and Merck Sign Technology Collaboration |
| April 3 |
New Data Show Early Non-Response to Antipsychotic Treatment May Be
Strong Predictor of Subsequent Non-Response for People with
Schizophrenia |
| April 3 |
Nipent Acquisition by Hospira is Complete |
| April 3 |
Wyeth Completes Purchase of Wyeth K.K. Japan |
| April 3 |
MediVas Announces Achievement of Milestone in Connection With Merck
Agreement |
| April 3 |
New Data Confirm That Use of Levemir Can Limit Weight Gain |
| April 3 |
Fewer Children and Teens Received Antidepressants Following FDA
Warnings |
| April 3 |
Bristol-Myers Squibb Gets Civil Investigative Demand From FTC |
| April 3 |
Boston Scientific Announces Japanese Approval for the Taxus
Express2 Stent System |
| April 3 |
Lilly Announces Completion of Hypnion Acquisition |
| April 3 |
Crucell Announces European Protein Distribution Deal with Talecris
Biotherapeutics |
| April 3 |
Managing Diabetes is Now Simpler and More Convenient with New
Premixed Insulin Analogue |
| April 4 |
Innocoll Receives FDA Approval to Commence Phase 2 Clinical
Development with its CollaRx Bupivacaine Implant for the Management
of Post-operative Pain |
| April 4 |
Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b
Study of Basiliximab in Patients with Steroid-Refractory Ulcerative
Colitis |
| April 4 |
Applied DNA Sciences Acquires Applied DNA Sciences Europe Ltd. |
| April 4 |
Survival Data Available from Erbitux Study in First-Line Treatment
of Advanced Head and Neck Cancer |
| April 4 |
Lux Biosciences Initiates Clinical Trials of Its Second Pivotal
Stage Program |
| April 4 |
Effect of Hormone Therapy on Risk of Heart Disease May Vary by Age
and Years Since Menopause |
| April 4 |
Britain's OFT Launches Market Study Into UK Medicines Distribution |
| April 4 |
Icagen Terminates Phase III ASSERT Study |
| April 4 |
New Analysis of Data from WHI Provides Reassurance With Respect to
Coronary Heart Disease For Newly Menopausal Women Considering
Hormone Therapy |
| April 4 |
Study Suggests Some Drug Resistance to Influenza B Medications |
| April 4 |
Combination Treatment for Migraine More Effective Than Single
Medications |
| April 4 |
pSivida Signs $165 Million(US) Collaborative Research and Licensing
Agreement with Pfizer |
| April 4 |
Genzyme Files for Expanded Label for Campath as First-Line
Treatment For B-CLL Patients |
| April 4 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot
Study of MM-093 in Patients with Autoimmune Uveitis |
| April 4 |
Manhattan Pharmaceuticals Announces License Agreement and Expanded
Pipeline |
| April 4 |
Marshall Edwards, Inc. Renegotiates Annual License Payments for
Phenoxodiol |
| April 4 |
AVEO Enters into Worldwide License and Development Agreement with
Schering- Plough for AV-299, AVEO's Novel Anti-HGF Antibody |
| April 4 |
Metabasis Therapeutics Initiates a Proof of Concept Study for
MB07803, Its Second Product Candidate for the Treatment of Type 2
Diabetes |
| April 4 |
Genta Appeals FDA Decision on Genasense in CLL |
| April 4 |
Pharmacyclics' Xcytrin New Drug Application for Treatment of Lung
Cancer Brain Metastases to Be Filed Over Protest |
| April 4 |
Shionogi Announces Revisions to the Second Medium-Term Business
Plan |
| April 4 |
Shionogi & Co., Ltd. - Notice of Revision of Results Forecast
for the Year Ended March 31, 2007 |
| April 4 |
Bayer Healthcare Pharmaceuticals Officially Launches in the United
States |
| April 4 |
Roche to Acquire BioVeris for $21.50 Per Share |
| April 4 |
Roche to Acquire Bioveris to Expand Its Leading ECL Immunochemistry
Business Into New Market Segments |
| April 4 |
Meditrina Pharmaceuticals, Inc. Initiates Phase II Trial and Raises
$4.4M in Initial Funding |
| April 4 |
DOR BioPharma Announces Initiation of Clinical Development Program
for Oral Leuprolide |
| April 4 |
Biopure Announces CEO's Prepared Remarks at Annual Meeting of
Stockholders |
| April 4 |
Crucell Announces Start of Rabies Phase I Antibody Cocktail
Clinical Study in India four months after launching initial US
Trial |
| April 4 |
New Report: Allowing the Government to Negotiate Medicare Drug
Prices Would Save Taxpayers $30b Annually |
| April 4 |
Medifacts International Divests CRO Division |
| April 4 |
Regulatory Approval to Start Pediatric Clinical Trials for Japanese
Encephalitis (JE) Vaccine in India Obtained |
| April 5 |
ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel
Emulsion) |
| April 5 |
One of the Largest-Ever Parkinson's Disease Studies Initiated
Across the United States |
| April 5 |
Pegintron Approved in China for Treating Chronic Hepatitis B |
| April 5 |
Wyeth Provides Guayama Update |
| April 5 |
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival
Compared With High-Dose Steroid for Multiple Myeloma Treatment |
| April 5 |
Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial
Advances to Next Phase |
| April 5 |
Multiple Myeloma Clinical Trial Closes Early Due to Significantly
Superior Results of Comparative Treatment |
| April 5 |
R&D Directions Magazine Names Rexahn's Leading Cancer
Candidate, RX-0201 (Archexin) among ''100 Great Investigational
Drugs'' |
| April 5 |
BioMS Medical's Pivotal Multiple Sclerosis Trial Receives Positive
Interim Safety Analysis |
| April 6 |
ARIAD Provides Update Regarding AP23573 Phase 3 Trial in Metastatic
Sarcoma |
| April 6 |
VaxGen to Receive $11M, Release From Potential Liabilities Under
Settlement Agreement with U.S. Government; Conference Call
Scheduled for Today |
| April 6 |
MediMedia USA Acquires Majority Interest in Complete Healthcare
Communications, Inc. (CHC) |
| April 6 |
Treatment-Induced Growth Factor Causes Cancer Progression |
| April 6 |
Sen. Grassley Seeks Marketing and Safety Documents from Major Drug
Maker |
| April 6 |
Statins Linked to Lower Risk of Infection |
| April 6 |
Childhood Immunization Against Pneumonia Cuts Hospital Admissions
by Almost 40% |
| April 6 |
Barr Confirms Patent Challenge of Ambien CR |
| April 6 |
FDA approves Cangene's HepaGam B for a Second Indication; for Use
in Hepatitis B-positive Liver Transplant Recipients |
| April 6 |
Abbott Announces FDA Approval of a New Coated Niaspan Tablet |
| April 6 |
Wyeth Provides Update on FDA Review of the Torisel New Drug
Application |
| April 6 |
FDA MedWatch Announces Tigan (trimethobenzamide hydrochloride) -
Product Market Withdrawal Due to Lack of Evidence of Effectiveness |
| April 9 |
Melior Enters Research Collaboration With Pfizer |
| April 9 |
Ithaka Acquisition Corp. Affiliates Announce Purchase Plan |
| April 9 |
Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial
Evaluating Glufosfamide in Patients With Soft Tissue Sarcoma |
| April 9 |
Patent and Trademark Office Issues Notice of Allowance on Barr's
Reissue Application for Seasonale '032 Patent |
| April 9 |
Caliper Life Sciences to Explore Novel Indications for Drug
Candidates |
| April 10 |
GSK and Adolor Announce Preliminary Results from Phase 3 Safety
Study of Alvimopan (Entereg/Entrareg) |
| April 10 |
Public Citizen Calls on FDA to Stop Illegal Celebrex Television
Advertisement |
| April 10 |
Media Advisory: Voluntary Drug Recall - Ortho-McNeil
Pharmaceutical, Inc. Issues a Nationwide Recall of Grifulvin
V/Griseofulvin Oral Suspension |
| April 10 |
Abbott Agrees With World Health Organization (WHO) Director-General
to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir) |
| April 10 |
Mylan Increases Fiscal 2007 Adjusted Diluted EPS Guidance to $1.60
- $1.63 Excluding Any Contribution from the Recent Launch of
Amlodipine Besylate |
| April 10 |
Boehringer Ingelheim Expands GeneGo Licenses to Global Agreement |
| April 10 |
FermaVir Pharmaceuticals, Inc. Signs Definitive Agreement to Be
Acquired by Inhibitex, Inc. |
| April 10 |
Abbott Opens New Biotechnology Manufacturing Facility in Puerto
Rico |
| April 10 |
Pfizer and Renovis Extend Research Collaboration to Identify Small
Molecule VR1 Antagonists |
| April 10 |
Information Policy Institute Finds Restrictions on
Provider-Identifiable Healthcare Data Are Anti-Competitive and Will
Not Lower Drug Prices |
| April 10 |
Cardinal Health Completes Sale of Pharmaceutical Technologies and
Services Segment to The Blackstone Group |
| April 10 |
Data Available from Erbitux Phase III Study in First-Line Treatment
of Advanced Pancreatic Cancer |
| April 10 |
FDA Announces Important Notice About Combivir and Ziagen |
| April 10 |
Galapagos Issues 628,058 New Shares Related to Inpharmatica
Acquisition and Warrant Exercise |
| April 10 |
U.S. District Court Grants Extension for Consideration of
Amlodipine Besylate Exclusivity |
| April 11 |
Neurochem's Eprodisate (Kiacta) PDUFA Date Extended Three Months by
FDA |
| April 11 |
Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs
Advisory Committee Meeting on Arcoxia (etoricoxib) |
| April 11 |
Schering-Plough Addresses Major Milestones and Challenges in
Treatment of Patients With Chronic Hepatitis C |
| April 11 |
Transgene and Roche Enter Partnership on Therapeutic Vaccines
Against HPV-Mediated Diseases |
| April 11 |
Illumina Announces Consolidation of Connecticut Operations |
| April 11 |
inVentiv Health Announces the Consolidation and Strengthening of
its Sampling and Regulatory Compliance Offerings |
| April 11 |
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug
Application for Davanat/ 5-FU |
| April 11 |
Genaera Corporation Completes Strategic Review and Announces Plan
to Focus Resources on Obesity and Asthma Programs |
| April 11 |
District Court Calls for GlaxoSmithKline to Release Bond Amount of
$3 Million to Roxane Laboratories Relating to the Launch of Generic
Fluticasone Propionate |
| April 11 |
Phenomenex, Global Leader in Separation Sciences Technology,
Announces Acquisition of Two Companies in Italy and Denmark |
| April 11 |
Publicis Groupe Acquires The McGinn Group, Bolstering Manning
Selvage & Lee's Strengths inCorporate Communications |
| April 11 |
Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil
Powder For Oral Suspension in Canada |
| April 11 |
Interpublic Acquires Best-in-Class Search Marketing Agency |
| April 11 |
Third Point Demands that PDLI CEO Mark McDade be Terminated or
Resign; Insists that Company Pursue Cost Cutting Measures and
Consider Alternatives to Maximize Shareholder Value |
| April 12 |
Genentech Announces First Quarter 2007 Results |
| April 12 |
Array BioPharma Achieves Milestone for Dosing MEK Inhibitor,
ARRY-704, in Phase 1 Clinical Trial |
| April 12 |
Indevus and Valera Announce Merger Exchange Ratio |
| April 12 |
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use
in Vaccine Programs |
| April 12 |
MedImmune Explores Strategic Alternatives |
| April 12 |
Zanaflex (tizanidine hydrochloride) Tablets and Capsules - Changes
to the Contraindications and Warnings Sections of the Approved
Product Labeling |
| April 12 |
U.S. Federal Circuit Court Affirms Judgment for Allergan, Inc. and
Roche Palo Alto, LLC against Apotex, Inc., Apotex Corp., and Novex
Pharma in Ketorolac Patent Infringement Lawsuit |
| April 12 |
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth
Factor, Promacta, in ITP |
| April 12 |
A Genetic 'Gang of 4' Drives Spread of Breast Cancer |
| April 12 |
Lupin Receives US FDA Approval for Novel Formulation of Suprax
Suspension |
| April 12 |
Chromos Plans to Restructure |
| April 12 |
Virax to Receive Milestone Payment from Transgene through Co-X-Gene
Technology Licence |
| April 13 |
GSK Announces FDA Approval of Altabax (Retapamulin Ointment), 1% |
| April 13 |
FDA Advisory Committee Recommends Against Approval for Merck's NDA
for Arcoxia (etoricoxib) |
| April 13 |
Merck Anticipates Higher Than Expected First-Quarter Results;
Raises Full-Year 2007 Earnings Per Share Guidance |
| April 13 |
FDA to Hold Public Hearing on Medication Guide Program |
| April 13 |
CDC Changes Recommendations for Gonorrhea Treatment Due to Drug
Resistance |
| April 13 |
pSivida Sells AION Diagnostics Subsidiary |
| April 13 |
National Kidney Foundation Releases Preliminary Anemia Guideline
Update |
| April 13 |
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of
Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment |
| April 13 |
Eisai Withdraws Application for Additional Indication of Aricept
for Treatment of Severe Alzheimer's Disease in Europe |
| April 13 |
Syndax Pharmaceuticals, Inc. Licenses Selective Histone Deacetylase
Inhibitor MS-275 |
| April 13 |
Avista Capital Partners Completes Acquisition of BioReliance
Corporation from Invitrogen Corporation |
| April 13 |
Federal Court Dismisses Vioxx Securities Class Action |
| April 13 |
FDA Approves New Dose of Risperdal Consta for Schizophrenia
Treatment |
| April 13 |
Positive Results Prompt US National Cancer Institute to Make Glivec
Available to Patients in Post-Surgical GIST Study |
| April 13 |
Invitrogen Completes Divestiture of BioReliance |
| April 16 |
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales
and EPS Guidance |
| April 16 |
Cytochroma and Genzyme Settle Lawsuit |
| April 16 |
Ariad Files Claim Against Amgen and Wyeth Alleging Infringement of
NF-(kappa)B Patent by Enbrel and Kineret |
| April 16 |
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants
Priority Review Status |
| April 16 |
Avant Restructures Organization to Focus Resources on Core Programs
and Operations |
| April 16 |
Interim Results Presented at EASL from PROVE 1 Clinical Trial of
Investigational Drug Telaprevir in Patients with Genotype 1
Hepatitis C |
| April 16 |
U.S. Government Notifies Bavarian Nordic of Intent to Acquire 20
Million Doses of Imvamune Smallpox Vaccine |
| April 16 |
Boston Scientific Resolves CRM Warning Letter Deficiencies |
| April 16 |
Results of Extraordinary General Meeting held on 16 April 2007 |
| April 16 |
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving
Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual
Meeting |
| April 17 |
Reclast Receives US Approval as a Highly Effective Treatment for
Patients with Paget's Disease of the Bone |
| April 17 |
Novel Therapeutic Candidate Identified Through Pharmacopeia
Collaboration Enters Development |
| April 17 |
VioQuest Pharmaceuticals Signs Definitive Agreement for Sale Valued
Up to $3 Million of Chiral Quest Subsidiary |
| April 17 |
Johnson & Johnson Reports 2007 First-Quarter Results: Sales
Increase of 15.7% and EPS of $.88 Versus $1.10 a Year Ago;
Excluding Special Items, EPS was $1.16, an increase of 17.2% * |
| April 17 |
Cegedim SA's Proposed Acquisition of Dendrite International, Inc.
Clears U.S. Antitrust Review |
| April 17 |
FDA Approves New Actonel Dose to Treat and Prevent Postmenopausal
Osteoporosis |
| April 17 |
Merck Submits New Cross-Protection Data for Gardasil to the FDA and
Seeks New Indications for Vaginal and Vulvar Cancers |
| April 17 |
Eisai Announces Completion of Acquisition of Morphotek |
| April 17 |
Catalina Marketing Agrees to be Acquired by Hellman & Friedman
for $32.50 Per Share in Cash |
| April 17 |
FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza |
| April 17 |
Warner Chilcott Announces Settlements in Principle of Antitrust
Suits Brought by States and Indirect Purchasers |
| April 17 |
Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100
Percent Protection Against Precancerous Lesions Caused By
Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than
Five Years |
| April 17 |
GE Healthcare Acquires Wave Biotech LLC, Broadening Capabilities in
Growing Biopharmaceutical Manufacture Segment |
| April 17 |
Patheon Announces Plans to Restructure Canadian Site Network |
| April 17 |
FDA Approves First U.S. Vaccine for Humans Against the Avian
Influenza Virus H5N1 |
| April 18 |
Abbott Reports 15.5 Percent Sales Growth in First Quarter |
| April 18 |
MCF Corporation Closes on the MedPanel, Inc. Transaction |
| April 18 |
Anemia Treatment for Patients with Kidney Disease Can Differ by
Dialysis Facility Type |
| April 18 |
Benefits of Antidepressants Appear Greater Than Risks for Children,
Teens |
| April 18 |
Cortex's AMPAKINE CX717 Toxicology Data Package Submitted to FDA |
| April 18 |
Health Industry Insights Identifies Pharmaceutical Industry's Top
Roadblocks to RFID Adoption |
| April 18 |
Roche Posts Strong First Quarter Sales – Upgrade of Core
Earnings Per Share Outlook for 2007 |
| April 18 |
Breakthrough Cancer Drug Avastin Approved in Japan for Use in
Advanced or Recurrent Colorectal Cancer |
| April 18 |
Phoenix Marketing International's Health Care Practice Quantifies
Consumer Confidence in Pharmaceutical and Medical Websites |
| April 18 |
INC Research Expands Therapeutic Focus with Infectious Disease
Capabilities |
| April 18 |
Cell Therapeutics, Inc. to Pay United States $10.5 Million to
Resolve Claims for Illegal Marketing of Cancer Drug |
| April 18 |
CTI Settles Qui Tam Suit with Government, Suit Against Medicare
Reimbursement Advisor to Recover Damages Filed |
| April 18 |
S&P: Fourth Annual "Top 10 Pharma Products To Watch" Report
Published |
| April 18 |
Large Numbers of People Are Not Very Confident in Their Own
Knowledge and the Safety of Prescription Medications and This Often
Leads to Non-Adherence |
| April 18 |
New Report Shows Prices for Top Medicare Part D Drugs Grew by 9.2
Percent in Past Year |
| April 18 |
New Study Reveals Generic Drugs Continue Entering Market as
Authorized Generic Competition Increases |
| April 18 |
Entelos Acquires SPRM Compound Series |
| April 18 |
Med Ad News Honors Health-Care Advertisers at 18th Annual Manny
Awards |
| April 19 |
Baxter Reports Strong First Quarter Financial Results and Boosts
Full-Year Outlook |
| April 19 |
Schering-Plough Reports Financial Results for First Quarter of 2007 |
| April 19 |
Wyeth Reports Earnings Results for the 2007 First Quarter |
| April 19 |
Wyeth Responds to Special Report Published in New England Journal
of Medicine |
| April 19 |
Neurochem Update on the North American Phase III Clinical Trial for
Tramiprosate (ALZHEMED) for the Treatment of Alzheimer's Disease |
| April 19 |
Schering-Plough Announces Initiation of Two Phase III Clinical
Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348) |
| April 19 |
PhRMA Statement on Families USA Reports |
| April 19 |
Schering-Plough Announces Zetia Approved in Japan for Treatment of
High Cholesterol |
| April 19 |
Antisoma Announces Global Agreement with Novartis for Cancer Drug
AS1404 |
| April 19 |
Gilead Sciences Announces First Quarter 2007 Financial Results |
| April 19 |
Novartis Expands Late-stage Oncology Pipeline With AS1404, a Novel
Agent Shown to Break Down Blood Vessels That Support Tumor Growth |
| April 19 |
National Medical Association Seeks to Increase Diversity in
Clinical Trials |
| April 19 |
Access Pharmaceuticals Signs Definitive Merger Agreement With
Somanta Pharmaceuticals |
| April 19 |
Ovarian Cancer Deaths Due to HRT In UK Since 1991 |
| April 19 |
NeoPharm, Inc. Announces Strategic Reassessment and Reorganization |
| April 19 |
Merck Reports Strong Financial Results for First-Quarter 2007 |
| April 19 |
Aranesp "145 Study" Shows No Difference in Survival in Patients
with Small-Cell Lung Cancer |
| April 19 |
First-of-its-Kind Email Newsletter Recaps the Issues Raised by
Pharmaceutical Industry Bloggers |
| April 19 |
BTG signs agreement with Novacea and KuDOS for AQ4N |
| April 19 |
Johnson & Johnson Pharmaceutical Research & Development,
L.L.C. Breaks Ground on New Facility |
| April 20 |
Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year
Expectations for 2007 and 2008 |
| April 20 |
FDA Grants Full Approval for DepoCyt for the Treatment of
Lymphomatous Meningitis |
| April 20 |
Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim |
| April 20 |
ZARS Announces First European Marketing Approval and License
Agreement With EUSA Pharma for Rapydan |
| April 20 |
The Lancet Publishes PREVAIL Study Results Showing Lovenox
Superiority Over Unfractionated Heparin for Reducing the Risk of
Venous ThromboEmbolism in Patients With Acute Ischemic Stroke |
| April 20 |
AHIP Advances New National Strategy to Improve Health Care Safety
and Quality |
| April 20 |
Abbott Submits New Drug Application for Combination
Niaspan/Simvastatin Tablet |
| April 20 |
FDA Announces Audio Broadcasts on Emerging Drug Safety Information |
| April 23 |
Texas Court Dismisses Claim of Vioxx User Who Said Merck Failed to
Properly Warn of the Alleged Risks |
| April 23 |
KaloBios Licenses Humaneering Technology to Major Pharmaceutical
Company |
| April 23 |
CollaGenex Pharmaceuticals Provides Update on Examination of
Incyclinide Patent Application |
| April 23 |
AstraZeneca Announces Decision to Discontinue Collaboration With
AtheroGenics Regarding AGI-1067 |
| April 23 |
AstraZeneca PLC: First Quarter Results 2007 |
| April 23 |
AstraZeneca to Acquire MedImmune For $58 Per Share in a Fully
Recommended, All-cash Transaction with a Total Enterprise Value of
$15.2 Billion |
| April 23 |
Novartis with Dynamic Growth in the 2007 First Quarter |
| April 23 |
FDA MedWatch: Avastin (bevacizumab) and Formation of
Tracheoesophageal Fistula in a Recent Clinical Study in Patients
with Limited-stage Small Cell Lung Cancer |
| April 23 |
Application for an Additional Indication of CombinationTherapy of
Glufast® and Insulin Sensitizer in Japan |
| April 23 |
Many Americans Deeply Skeptical Of Pharmaceutical Companies--
Motives For Supporting Non-Profits |
| April 23 |
Synosia Therapeutics Announces Second Major Pharmaceutical Deal |
| April 23 |
Actavis Completes Acquisition of Abrika Pharmaceuticals in the US |
| April 23 |
The Westaim Corporation to Undertake Review of Business Strategy |
| April 24 |
Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7
Billion |
| April 24 |
Astex Grants Cytochrome P450 License to Glaxosmithkline |
| April 24 |
FDA Approves Alpharma's Kadian New 10mg Strength |
| April 24 |
FDA Approves First Generic Versions of Ambien (Zolpidem Tartrate)
for the Treatment of Insomnia |
| April 24 |
Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter
Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adjusted
EPS of $0.74*, Excluding the Effect of the Cerexa Acquisition |
| April 24 |
MultiCell Signs License Agreement With Eisai Japan to Use Fa2N-4
Cell Line for Drug Discovery/ADMETOX Applications |
| April 24 |
Drug Reps Use Friendship to Influence Doctors, Says Faculty Member |
| April 24 |
China Aoxing Pharmaceutical Company Signs Letter of Intent to
Acquire Shijiazhuang Le Ren Tang Pharmaceutical Ltd. |
| April 24 |
Drug Company Sales Visits Influenced Doctors, Study Finds |
| April 24 |
Acomplia (rimonabant) is Reimbursed in Switzerland for the
Treatment of Type 2 Diabetics Overweight Patients and for the
Treatment of Patients with Obesity |
| April 24 |
SEC Charges Husband of Amgen Vice President with Insider Trading |
| April 24 |
Akzo Nobel NV (NL) - Refocused Akzo Nobel reports strong first
quarter results |
| April 24 |
Elan Reports First Quarter 2007 Financial Results |
| April 24 |
Amarin Reports Top-Line Results of two Phase III Studies of
Miraxion in Huntington's Disease |
| April 24 |
SVB Silicon Valley Bank Provides $19 Million in Buyout Financing
for Vector Capital's Acquisition of Tripos |
| April 24 |
Dey, L.P. Reaches Settlement with Commonwealth of Massachusetts on
Pricing Litigation |
| April 24 |
Vernalis plc Announces Intent to Delist from The Nasdaq Stock
Market and to Deregister and Terminate its U.S. Reporting
Obligations under the Securities Exchange Act of 1934 |
| April 24 |
Merck's Plan to Win Has Company Poised to Reclaim Position as
Industry Leader, Chairman and CEO Tells Stockholders |
| April 24 |
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the
Prevention of Postmenopausal Osteoporosis |
| April 25 |
QLT Announces that CHMP Will Recommend to the European Commission
that Occult Indication be Deleted from the Visudyne Label in
European Union |
| April 25 |
Shire plc: First Quarter Results - Strong Start to the Year With
Upgraded Guidance Now Including New River |
| April 25 |
FDA Advisory Committee Recommends Accelerated Approval of Pfizer's
Maraviroc for Treatment-Experienced Patients Infected with
CCR5-tropic HIV-1 |
| April 25 |
AmerisourceBergen Receives DEA Order to Temporarily Halt
Distribution of Controlled Substances from Its Orlando, Florida
Facility |
| April 25 |
Biotech Drug Spending Increases 21 Percent Even as Growth in Rx
Expenditure Slows |
| April 25 |
QLT Announces Q1 Results for 2007 |
| April 25 |
PhRMA Statement on Medicare Trustees Annual Report |
| April 25 |
FDA Sends Alcon Warning Letter Over Ciprodex Literature |
| April 25 |
Medtronic Responds to ''Inequitable Conduct'' Decision by U.S.
District Court in Stent Litigation |
| April 25 |
Novartis Expands Portfolio of Respiratory Medicines |
| April 25 |
Dyadic Announces Discovery of Potentially Material Operational and
Financial Improprieties at its Hong Kong and Mainland China
Operations |
| April 25 |
New Indication for Singulair (montelukast sodium) Approved to
Prevent Exercise-induced Bronchoconstriction |
| April 25 |
GlaxoSmithKline: Results Announcement for the First Quarter 2007 |
| April 25 |
Q1/2007: Merck KGaA Total Revenues Grow 37% to EUR 2.2 Billion |
| April 25 |
Journal of the American Medical Association Publishes MERLIN
TIMI-36 Results |
| April 25 |
New Data Supports Safety of Anti-anginal Drug but Not Its
Effectiveness in Reducing Recurrent Major Cardiac Events in
Patients with Acute Coronary Syndromes |
| April 25 |
Orion's Partner Discontinues Development of Levosimendan (Simdax)
in the US |
| April 25 |
Genzyme Reports Significant Revenue and Earnings Growth in First
Quarter |
| April 25 |
New Trial Expands Evidence for Glucobay in Prevention of
Cardiovascular Diseases |
| April 25 |
FDA Approves Labeling Update for Orencia (abatacept) to Inhibit
Structural Joint Damage in Adults with Moderate to Severe
Rheumatoid Arthritis |
| April 25 |
Health Canada Approves Lipitor for the Reduction of the Risk of
Heart Attack in Patients with Coronary Heart Disease |
| April 25 |
Large Numbers of People Do Not Trust the Institutions They Identify
as Most Responsible for Drug Safety |
| April 25 |
Questions Over Zyprexa Clinical Trial Data Underscore Need for
Congress to Act Now on Drug Safety Legislation |
| April 25 |
Roche Carolina Inc. to Expand Manufacturing at Florence Facility |
| April 25 |
Solvay Pharmaceuticals Files Tedisamil, a New Cardiometabolic
Product for the Treatment of Atrial Fibrillation and Atrial Flutter |
| April 25 |
Kirin's NESP Long-Acting Erythropoiesis Stimulating Agent Injection
Syringe Receives Approval in Japan |
| April 25 |
BioLife Solutions Grants Product License to Centocor Research &
Development, Inc. |
| April 26 |
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to
Develop and Commercialize Anticoagulant and Metabolic Compounds |
| April 26 |
Pfizer Subsidiary Pleads Guilty to Kickback Violation and Is
Sentenced to Pay Criminal Fine of $19.68 Million |
| April 26 |
James M. Cornelius Elected Bristol-Myers Squibb CEO |
| April 26 |
Roche Update on Tamiflu for Pandemic Influenza Preparedness |
| April 26 |
ImClone Systems Reports First Quarter 2007 Financial Results |
| April 26 |
Bayer Exceeds Consensus Estimates for the First Quarter of 2007 |
| April 26 |
Physician Ties to Drug Industry Stronger Than Ever |
| April 26 |
New Finance Committee Report Focuses on Drug Company Grants for
Medical Education |
| April 26 |
Bristol-Myers Squibb Company Reports First Quarter 2007 Financial
Results |
| April 26 |
Bristol-Myers Squibb Company Reports First Quarter 2007 Financial
Results |
| April 26 |
Phoenix Marketing International's Health Care Practice Quantifies
Visitor Confidence in Pharmaceutical Websites |
| April 26 |
Cerus to Explore Strategic Alternatives for Its Immunotherapy
Programs |
| April 26 |
Acomplia (rimonabant) is Approved in Brazil for the Treatment of
Obese Patients, or Overweight Patients with Associated Risk
Factors, Such as Type 2 Diabetes or Dyslipidemia |
| April 26 |
Pfizer Focused on Delivering the Value Customers Expect and
Shareholders Deserve, CEO Kindler Tells Shareholders |
| April 26 |
The New ALTANA Starts with Good First Quarter 2007 |
| April 27 |
Abbott's Humira (Adalimumab) Receives Positive Opinion from
European Medicines Agency for the Treatment of Crohn's Disease |
| April 27 |
Invega Receives Positive Opinion From European Committee for Human
Medicinal Products for Treatment of Schizophrenia |
| April 27 |
Hollis-Eden Pharmaceuticals Announces Reorganization |
| April 27 |
ArQule and Kyowa Hakko Kogyo Sign Exclusive License Agreement in
Asia for ARQ 197, c-Met Inhibitor |
| April 27 |
FDA Sends Warning Letter to DUSA Pharmaceuticals Over Actinic
Keratosis Treatment Ad |
| April 27 |
Cipher Pharmaceuticals Receives Approvable Letter from FDA for
CIP-ISOTRETINOIN |
| April 27 |
Kyowa Hakko Fiscal 2006 Operating Income up 20.2% |
| April 27 |
Submission of NDA for Istradefylline(KW-6002), an
Investigational Anti-Parkinson's Disease Drug |
| April 27 |
Pharmasset Prices Initial Public Offering |
| April 27 |
Inex Pharmaceuticals Announces Expected Completion Date for
Spin-out of Tekmira Pharmaceuticals Corporation |
| April 27 |
EMEA Issues 15 Opinions |
| April 27 |
Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin
to Leave the Company |
| April 27 |
Merck Receives Non Approvable Letter from FDA for Arcoxia
(etoricoxib) |
| April 27 |
Schering-Plough Announces EU Approval Of Two New Formulations Of
Aerius (Desloratadine) |
| April 27 |
Werner Wenning at the Annual Stockholders’ Meeting in
Cologne: Bayer Off to an Excellent Start in 2007 |
| April 27 |
Blogs Scrutinize Relationships Between Physicians and
Pharmaceutical Sales Reps, Drug Companies and Non-Profits |
| April 27 |
Merck Receives Non Approvable Letter from FDA for Arcoxia
(etoricoxib) |
| April 27 |
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study |
| April 27 |
FDA Approves Invega for Long-Term Maintenance Treatment of
Schizophrenia |
| April 27 |
Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting |
| April 27 |
Ark Therapeutics Group Announces EMEA Decision on Cerepro Phase II
Filing |
| April 29 |
FDA Approves Once-Daily Veramyst (fluticasone furoate) Nasal Spray
for Treatment of Seasonal and Year-Round Allergy Symptoms in Adults
and Children as Young as Two Years |
| April 29 |
Inspire Announces FDA Approval Of AzaSite |
| April 30 |
InSite Vision Announces FDA Approval for AzaSite Approval Triggers
$19 Million Milestone Payment |
| April 30 |
Sangamo BioSciences Announces Research and License Agreement With
Genentech for ZFP Technology for Protein Pharmaceutical Production |
| April 30 |
FDA Approves Product to Treat Common Bleeding Disorder |
| April 30 |
Newly Published Study Reveals Femara Improves Chances for Harder to
Treat Early Breast Cancer Relapse in Postmenopausal Women |
| April 30 |
Sebivo (Telbivudine) Approved in European Union as a New Treatment
for Chronic Hepatitis B Patients |
| April 30 |
GlaxoSmithKline and Wellcome Trust Announce Partnership to Target
Drug-Resistant Hospital Infections |
| April 30 |
FDA Approves Lantus SoloStar - A New Prefilled Disposable Insulin
Pen For Use With Lantus In People With Type 1 And Type 2 Diabetes |
| April 30 |
Duramed's Enjuvia (Synthetic Conjugated Estrogens, B) Tablets
Receives Two New FDA Approvals |
| April 30 |
Court Grants Hemosol Further Stay Extension |
| April 30 |
Sebivo Approved in European Union as a New First-line Treatment for
Chronic Hepatitis B |
| April 30 |
Cardiome Announces In-Licensing Agreement With Eli Lilly and
Company |
| April 30 |
Humate-P Approved to Prevent Excessive Bleeding in Patients with
von Willebrand Disease Undergoing Surgery |
| April 30 |
Mylan Remains the Only Approved ANDA for All Strengths of
Amlodipine Besylate Tablets |
